Media Details

  • Home
  • Media
  • Details
  2020-10-15 20:13:42

Ho Wah Genting Berhad and World Leading IVD manufacturer Wuhan Easydiagnosis Biomedicine Co Ltd partnership bears fruits

KUALA LUMPUR, 15 October 2020 – Wuhan Easydiagnosis Biomedicine Co Ltd (“Wuhan Easydiagnosis”), a leading manufacturer of in-vitro diagnostic devices based in Wuhan, China and specialising in the development, production, and distribution of point-of-care testing (“POCT”) or bedside testing rapid diagnostic reagents and related equipment to more than 20 countries, has authorized HWGB Biotech Sdn Bhd (fka HWG Consortium Sdn Bhd) (“HWGB Biotech”), a wholly-owned subsidiary of Ho Wah Genting Berhad (“HWGB” or the “Company”) (Bursa Stock Code: 9601) as the distributor of its COVID-19 nucleic acid test kits and nucleic acid extraction reagents in Malaysia with a validity period from 20 March 2020 to 20 March 2021.
On 13th October 2020, it was announced that the MOH had, in a technical report, shown that the COVID-19 test kits passed with 100% accuracy the sensitivity tests administered by the MOH.